Overview
- U.S. News published its inaugural ratings on Aug. 12, 2026, evaluating 20 telehealth companies that offer FDA‑approved, brand‑name GLP-1 medications and excluding firms that only sell compounded products.
- The outlet scored platforms on six weighted categories — clinical support, screening rigor, transparency, insurance assistance, supplemental care and customer satisfaction — using 14,161 data points and a survey of 1,251 recent telehealth GLP-1 users.
- Eleven companies earned the top “best” designation, with Amazon One Medical, Found, Mochi Health, Ro, Noom and WeightWatchers among the leaders, and Found, Amazon One Medical, Noom and Ro named category winners for clinical, insurance, supplemental and customer support respectively.
- Coverage and experts note clear benefits reported by many patients, including large weight losses and high user satisfaction, while clinicians and a JAMA letter have warned about impersonal care, variable follow-up, dosing errors and risks from rapid weight loss without integrated nutrition and muscle‑bone monitoring.
- The ratings give patients a comparative tool but do not eliminate complexity because some rated platforms may still offer compounded drugs, insurance acceptance and the level of real‑time clinician access vary widely, and patients should confirm baseline labs, follow‑up plans and insurance help before enrolling.